D. Cross

发表

Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

J. Lyons, N. Thompson, M. Squires, 2009, Molecular Cancer Therapeutics.

Biological characterization of AT 7519 , a small-molecule inhibitor of cyclin-dependent kinases , in human tumor cell lines

J. Lyons, N. Thompson, M. Squires, 2009 .

Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.

Paul G Wyatt, Valerio Berdini, V. Berdini, 2008, Journal of medicinal chemistry.

The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non‐small cell lung cancer

L. Fazal, M. Reule, J. Lyons, 2012, Cancer science.

Tissue distribution of anidulafungin in neonatal rats.

D. Cross, G. Chmielewski, C. Bowman, 2012, Birth defects research. Part B, Developmental and reproductive toxicology.

Comparison of cell death and adenosine triphosphate content as indicators of acute toxicity in vitro.

D. Cross, R. Kemp, R. Meredith, 1988, Xenobiotica; the fate of foreign compounds in biological systems.

Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M 1 -acetylcholine receptor agonist: A randomized cross-over trial

M. Congreve, F. Marshall, P. Nathan, 2021 .

Kinetics of ranitidine metabolism in dog and rat isolated hepatocytes.

D. Cross, K. Wilson, J. A. Bell, 1995, Xenobiotica; the fate of foreign compounds in biological systems.

An evaluation of reproductive and developmental toxicity of sitaxentan (thelin) in rats.

D. Cross, Mazin Derzi, F. Stavros, 2012, Birth defects research. Part B, Developmental and reproductive toxicology.

Drug–drug Interactions: An In Vitro Approach

D. Cross, M. Bayliss, 2004 .

Safety and Pharmacokinetics of HTL0018318, a Novel M1 Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects

D. Cross, G. Groeneveld, E. Klaassen, 2021, Drugs in R&D.

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.

Mladen Vinković, Paul G Wyatt, Jayne Curry, 2009, Journal of medicinal chemistry.

A COMMENTARY ON THE USE OF HEPATOCYTES IN DRUG METABOLISM STUDIES DURING DRUG DISCOVERY AND DEVELOPMENT*

D. Cross, M. Bayliss, 2000, Drug metabolism reviews.

Non-clinical safety assessment and toxicokinetics of voriconazole and anidulafungin in the juvenile rat: a combination study design in support of a Paediatric Investigation Plan.

D. Cross, G. Chmielewski, C. Bowman, 2012, Regulatory toxicology and pharmacology : RTP.

Evaluation of technetium-99m red blood cell labeling efficiency in adults receiving chemotherapy and the clinical impact on pediatric oncology patients.

G. Heller, D. Cross, M. P. White, 1998, Journal of nuclear medicine technology.

First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1‐receptor partial agonist for the treatment of dementias

M. Congreve, F. Marshall, P. Nathan, 2020, British journal of clinical pharmacology.

Evaluation of sitaxentan (Thelin®) toxicity in juvenile rats and regulatory interactions during the development of a European Medicines Agency pediatric investigation plan.

D. Cross, Mazin Derzi, F. Stavros, 2012, Regulatory toxicology and pharmacology : RTP.

An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension.

D. Cross, Mazin Derzi, David M Cross, 2012, Regulatory toxicology and pharmacology : RTP.

Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M1‐acetylcholine receptor agonist: A randomized cross‐over trial

M. Congreve, F. Marshall, P. Nathan, 2021, British journal of clinical pharmacology.

Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study

M. Congreve, F. Marshall, P. Nathan, 2021, Alzheimer's research & therapy.

A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease

M. Congreve, P. Maruff, P. Nathan, 2022, Alzheimer's & dementia.

From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s disease

Stephen R. Morairty, Robert T. Smith, G. Dawson, 2021, Cell.

The importance of hepatocytes in drug metabolism studies: an industrial perspective

D. Cross, M. Bayliss, 2000 .

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.

V. Berdini, P. Wyatt, L. Fazal, 2009, Journal of medicinal chemistry.

Juvenile toxicity assessment of anidulafungin in rats: an example of navigating case-by-case study design through scientific and regulatory challenges.

D. Cross, G. Chmielewski, C. Bowman, 2011, Birth defects research. Part B, Developmental and reproductive toxicology.